INOVIQ Ltd Issues New Options, Advances Cancer Diagnostics

Inoviq Ltd (AU:IIQ) has released an update.

INOVIQ Limited has announced the issuance of 375,000 options at A$1.00 each, expiring in July 2026, under its existing placement capacity, without requiring investor disclosure under the Corporations Act. The company confirms compliance with relevant provisions and the absence of undisclosed ‘excluded information.’ INOVIQ, a biotech firm specializing in advanced diagnostics and therapeutics for cancer, has made strides with its EXO-NET technology and clinical-stage diagnostics for ovarian and breast cancers.

For further insights into AU:IIQ stock, check out TipRanks’ Stock Analysis page.